Neuropace (NPCE) Q2 2026: RNS Revenue Grows 21%, AI Tools Enhance Clinical Adoption
Neuropace sustained robust growth in its core RNS system revenue, driven by expanding adoption and utilization within epilepsy centers, while advancing AI-enabled tools that enhance clinical decision-making. The company’s strategic focus on indication expansion and product innovation underpins a raised revenue outlook and improved profitability metrics. Upcoming regulatory milestones and expanding community access initiatives set the stage for accelerating growth beyond the current focal epilepsy market.
Summary
- Clinical Adoption Momentum: Expansion within level four epilepsy centers and growing patient pipeline signal durable market penetration.
- AI-Driven Differentiation: Launch of ECoG Assistant leverages proprietary intracranial EEG data to improve physician efficiency and treatment personalization.
- Regulatory Engagement Progress: Ongoing FDA interactions for IGE indication expansion maintain a clear pathway despite recent requests for additional clinical context.
Business Overview
Neuropace develops and commercializes the RNS System, an implantable, brain-responsive neurostimulation platform designed to treat drug-resistant epilepsy by detecting and responding to seizure activity in real time. The company generates revenue primarily through sales of the RNS System devices and associated services. Its business centers on the adult focal epilepsy indication, with ongoing efforts to expand into idiopathic generalized epilepsy (IGE) and pediatric populations.
Performance Analysis
In the second quarter of 2026, Neuropace reported total revenue of $22.8 million, marking a 17% increase year over year, with RNS System revenue growing 21.3% to $22.5 million. This growth reflects sustained adoption and utilization gains within established level four comprehensive epilepsy centers, which remain the primary revenue driver. The company also saw new all-time highs in active prescribers, accounts, and patient pipeline, indicating expanding market penetration and a healthy referral ecosystem.
Gross margin remained strong at 83.4% on a non-GAAP basis, slightly down from 84.0% the prior year, primarily due to modestly higher material costs offset by favorable pricing. Operating expenses increased by 3%, well below revenue growth, demonstrating operating leverage as Neuropace scales its commercial and R&D efforts. Adjusted EBITDA loss improved significantly to $2.8 million from $4.9 million a year earlier, reflecting disciplined expense management alongside investment in growth initiatives.
- Revenue Growth Drivers: Higher RNS system sales fueled by increased physician adoption and favorable pricing.
- Margin Stability: Gross margin resilience despite cost pressures highlights effective pricing and manufacturing management.
- Expense Leverage: Controlled operating expense growth supports improved adjusted EBITDA performance.
Overall, the quarter underscores Neuropace’s ability to grow its core business while investing in new technology and regulatory pathways that could unlock significant future revenue streams.
Executive Commentary
"Second-quarter performance showed continued momentum in our core RNS business driven by increased adoption within our current focal epilepsy indication. We also maintained strong financial discipline while continuing to invest in the long-term growth of the business and advance our product roadmap."
Joel Becker, Chief Executive Officer
"Adjusted operating expense increased approximately 3%, meaningfully below our revenue growth of 17%, reflecting continued operating leverage while we invest in the business. We remain focused on balancing investment in the company's long-term growth opportunities with continued financial discipline and progress toward sustainable profitability."
Patrick Williams, Chief Financial Officer
Strategic Positioning
1. Expanding Clinical Adoption Within Established Centers
Neuropace focuses on deepening penetration within level four epilepsy centers by increasing the number of epileptologists utilizing the RNS System and promoting advanced treatment modalities such as network stimulation and hybrid approaches with surgical therapy. This multi-pronged adoption strategy enhances utilization and supports sustainable growth within the company’s core adult focal epilepsy indication.
2. Community Access and Referral Pathways
The company is actively broadening its footprint into level three and community centers, establishing referral networks that facilitate patient flow to specialized centers for implantation and ongoing care. These initiatives not only support current indication growth but also lay groundwork for broader market expansion contingent on regulatory approval of new indications.
3. AI-Enabled Clinical Decision Support
The launch of ECoG Assistant, the first AI-based tool in Neuropace’s planned suite, leverages the company’s proprietary intracranial EEG data to streamline physician review of electrographic seizure patterns and circadian trends. Early clinical feedback highlights improved workflow efficiency and more informed individualized treatment decisions, reinforcing the RNS System’s differentiation and potential to drive increased adoption.
4. Regulatory Pathway for IGE Indication Expansion
Following the FDA’s request for additional clinical evidence, Neuropace is pursuing a Submission Issue Request (SIR) process to align on an amendment addressing subgroup analyses, patient-reported outcomes, and 24-month data demonstrating a 100% median reduction in generalized tonic-clonic seizures. Management remains optimistic about approval prospects and expects to submit the amendment promptly after the upcoming SIR meeting.
5. Next-Generation Platform and Remote Care Development
Neuropace is advancing its next-generation implantable device platform featuring expanded lead configurations and Bluetooth low energy communication, designed to enhance AI tool integration and remote programming capabilities. Remote care aims to reduce patient travel burden and improve physician efficiency, with FDA submission anticipated by year-end 2026.
Key Considerations
Neuropace’s second quarter results reflect a disciplined balance between growth and investment, with several critical factors shaping near- and medium-term prospects.
- Patient Pipeline Velocity: The company’s ability to convert patient referrals into implants is pivotal, with IGE and pediatric indications expected to accelerate adoption due to less invasive evaluation requirements.
- AI Integration Impact: The ECoG Assistant’s role in improving clinical workflow and outcomes may increase physician capacity and patient throughput, supporting volume growth.
- Regulatory Uncertainty: FDA requests for additional data introduce timing risk around IGE approval, but ongoing interactive engagement mitigates downside.
- Commercial Scaling Efficiency: Operating expense growth remains well controlled, indicating effective resource allocation amid expanding sales and R&D activities.
- Gross Margin Management: Modest cost pressures necessitate continued focus on pricing and manufacturing efficiencies to sustain margin expansion.
Risks
While Neuropace’s core business shows strength, risks include potential delays or unfavorable outcomes in the IGE regulatory process, competition from alternative neuromodulation therapies, and execution challenges in expanding community access. Additionally, supply chain or material cost volatility could pressure margins despite current management efforts.
Forward Outlook
For the third quarter of 2026, Neuropace expects RNS system revenue growth to approximate the first half’s 20% year-over-year pace. Full-year 2026 guidance has been raised to $99.5 million to $101.5 million in total revenue, reflecting improved service revenue visibility while maintaining a 21% to 23% growth outlook for core RNS revenue. Adjusted gross margin guidance has been increased to 82% to 83%, with operating expenses projected between $90 million and $92 million. Adjusted EBITDA loss is expected to improve to a range of $7.5 million to $8.5 million, underscoring progress toward sustainable profitability.
Takeaways
Neuropace continues to execute well on its core RNS System business, leveraging clinical adoption and AI innovation to drive growth and operational efficiency. The company’s proactive regulatory engagement and product development pipeline position it to unlock new market opportunities through indication expansion and enhanced remote care capabilities. Investors should monitor the FDA SIR meeting outcomes and the pace of community center adoption as key catalysts for 2027 growth acceleration.
- Core Business Strength: Consistent 20%+ RNS revenue growth evidences durable demand within adult focal epilepsy, supported by expanding prescriber and patient engagement.
- Strategic Innovation: AI tools like ECoG Assistant and next-generation platform development reinforce Neuropace’s competitive moat and potential for differentiated clinical outcomes.
- Regulatory Milestone Focus: The SIR meeting and subsequent amendment submission are pivotal near-term events that will clarify the timing and scope of IGE indication expansion.
Conclusion
Neuropace’s Q2 2026 results demonstrate disciplined execution across commercial, clinical, and product development fronts, underpinning a raised guidance profile and improved profitability metrics. The company’s strategic emphasis on AI-enabled differentiation and regulatory progress on IGE expansion offers a compelling growth runway beyond its established adult focal epilepsy market.
Industry Read-Through
Neuropace’s integration of AI into neuromodulation therapy and its focus on expanding access through community centers reflect broader industry trends toward personalized, data-driven treatment and decentralized care models. Its regulatory journey for IGE indicates the FDA’s evolving expectations for clinical evidence in neuromodulation, a signal other medtech companies should monitor. The company’s experience underscores the importance of proprietary data assets and AI in creating competitive advantage in the neurotechnology sector.